Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc.

NNASDAQ:OBX
12.36
USD
-0.20
(-1.59%)
-0.32EPS
Apr 01Next Earn

Important Dates

Obsidian Therapeutics, Inc.'s next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of March 31, 2026, Obsidian Therapeutics, Inc. has 61.60M shares outstanding.

Shares Outstanding61.60M

Financial Position

As of March 31, 2026, Obsidian Therapeutics, Inc. maintains a current ratio of 4.21, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.

Current Ratio4.21
Quick Ratio3.86
Debt / Equity-1.30

Financial Efficiency

These figures cover the twelve months ended March 31, 2026. The company generates approximately - - in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

Employee Count3.00

Stock Price Statistics

USD

These figures are as of the close on November 16, 2026.

50-Day Moving Average14.19

Income Statement

USD

These figures cover the twelve months ended March 31, 2026.

Pretax Income-19.63M

Balance Sheet

USD

As of March 31, 2026, Obsidian Therapeutics, Inc. holds 58.76M in cash and equivalents against 3.60M in total debt, resulting in a net debt position of -26.44M. Total book value stands at -276.20M, with working capital of 48.81M providing operational flexibility.

Cash & Cash Equivalents58.76M
Total Debt3.60M
Net Debt-26.44M
Equity (Book Value)-276.20M
Book Value Per Share-4.48
Working Capital48.81M

Cash Flow

USD

These figures cover the twelve months ended March 31, 2026. After subtracting - - in capital expenditures, free cash flow totaled -22.01M - equivalent to -0.36 per share.

Free Cash Flow-22.01M
FCF Per Share-0.36

Stock Splits

Obsidian Therapeutics, Inc.'s most recent stock split took place on July 13, 2026 with a 200:1 split ratio.

Last Split Date7/13/2026
Split Ratio200:1